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Abstract
Breast cancer is one of the leading causes of cancer-related mortality of
women in the United States. Since the majority of cancer deaths are due to
metastases rather than the primary tumor, a better understanding of the
biological mechanisms that lead to metastatic disease is critical to reduce
breast cancer associated mortality. Current adjuvant therapies use the same
broadly cytotoxic and targeted strategies against metastases as are used
against the primary tumor. However, resistance to chemotherapy due to the
cellular dormancy, high genotypic and phenotypic heterogeneity between
primary tumor and metastases as well as among individual metastases, and the
limitations in detection of disseminated tumor cells and micrometastases
significantly hinder the efficiency of currently available therapies. While it is
crucial to directly address the issue of metastatic dormancy and evaluate for
anti-metastatic therapy the relevance of molecular targets chosen based on
primary tumor profiling, it is also imperative to address metastasis-specific
mechanisms of growth and survival that are likely to be distinct from those of
the primary tumor. We believe that a three-pronged approach to therapy will be
necessary to deal with progressive disease: blocking of further dissemination
after diagnosis; eradication of disseminated tumor cells and prevention of the
dormant-to-proliferative switch of those remaining; and elimination of
established metastatic tumors. The implementation of this strategy requires a
greater depth of knowledge of metastasis driver and maintenance genes and
suggests the need for a “Metastasis Genome Atlas” project to complement the
current investigations into cancer genomic landscapes.
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Introduction
Breast cancer remains one of the leading causes of cancer-related
mortality among women in the US1. Since the primary tumor is
usually resected upon detection, the majority of mortality is due to
metastases. While 5-year relative survival for patients diagnosed
with localized breast cancer is 98.5%, it plummets to a dismal 25%
for patients with distant overt metastases1. Moreover, an estimated
20–50% of breast cancer patients diagnosed at an early stage are
expected to develop metastatic disease, which can occur years or
even decades after surgical removal of the primary tumor2. These
statistics indicate that the establishment of effective therapies that
target and prevent metastasis is of critical importance. Although the
past decade has seen significant advances in the development of
methods for detection and treatments of primary breast cancer, these
treatments are generally ineffective at eliminating metastatic disease.
This suggests either an inherent biological difference between primary tumors and distant metastases, a role of the microenvironment at
the secondary site in inducing therapeutic resistance, or likely both.
Recent progress in breast cancer treatment has been characterized
by a shift from cytotoxic drugs, which broadly target highly proliferating cells, to more targeted therapies designed to attack a specific molecule or pathway through a known mechanism of action.
This approach has been possible due to enormous technological
leaps in genome sequencing, molecular biology, cancer genetics,
genomics, and bioinformatics that allow for the identification of
individual patient mutations and clinically actionable targets from
tumor biopsy samples. Sequence information and patient-derived
xenograft methods have shown promise in identifying individualized therapeutic strategies that are effective for specific patients,
rather than the traditional population-based clinical strategies.
However, while various sequencing projects have characterized
the genomic landscape of breast cancer3,4, relatively little is known
about the somatic diversity of metastatic tumors. Expression profiling has revealed multiple subtypes with different prognostic
outcomes5 and led to identification of gene signatures that can stratify patients into groups with low- or high-risk for developing distant
metastatic disease6. Still, targeted therapies against metastases have
proven to be more challenging to develop compared to those targeting the primary tumor, since the critical driver molecules have not
yet been firmly established.
In this review, we discuss the major challenges facing the development of efficient therapies against metastasis. We also present a strategy that we believe will improve the targeting of metastatic disease:
blocking of further dissemination after diagnosis, eradication of disseminated tumor cells and prevention of the dormant-to-proliferative
switch of those cells not eradicated, and elimination of established
metastatic tumors. This strategy requires the elucidation of mechanisms that drive the establishment and maintenance of metastases.

Current anti-metastatic treatments and therapies in
development
Current therapies against metastatic breast cancer address different stages of tumor progression7. Broad-spectrum therapies, such as
cytotoxic chemotherapy, aim to kill actively dividing cancer cells.
According to an extensive meta-analysis, combination chemotherapy

can increase the 15-year survival rate of patients with early breast
cancer8. However, a substantial number of these patients develop
metastases or recurrent disease years after cessation of treatment,
indicating the presence of dormant cells at the secondary site that
are resistant to standard therapies. Therefore, the pathways that
allow cancer cells to remain viable in a dormant state would provide ideal targets for eliminating minimal residual disease and
preventing metastatic outgrowth after the cessation of treatment.
Among them are the survival pathways involving Src and p389–12.
Recent findings have shown that pharmacological inhibition of Src
family kinase (SFK) signaling inhibited the proliferative outgrowth
of dormant disseminated cells and the development of macrometastatic lesions12. Furthermore, dormant cell proliferation required
ERK1/2 activation, and the treatment of cells undergoing the
dormant-to-proliferative switch with the combination of Src inhibitor (AZD0530, saracatinib, AstraZeneca) and MEK1/2 inhibitor
(AZD6244, selumetinib, AstraZeneca) resulted in apoptosis of
dormant cells; neither of the inhibitors alone achieved this effect.
Since MEK1/2 is a well-described upstream activator of ERK1/2,
these observations complement previous reports showing that an
ERKlow/p38high signaling ratio promotes tumor cell quiescence
through a combination of signaling pathways promoting adaptive and
basal survival and G0-G1 quiescence11. These reports indicate that
therapies targeting signaling involved in the dormant-to-proliferative
switch might represent promising clinical interventions against
metastatic disease.
Major efforts of the pharmaceutical industry are now focused
on the development of novel targeted therapies that function in a
molecule-specific manner7. Examples of targeted therapies that are
presently in clinical use for breast cancer are aromatase/estrogen
synthase inhibitors (anastrozole, letrozole, and exemestane)13 and
trastuzumab (Herceptin®), a monoclonal antibody against epidermal
growth factor receptor 2 (ERBB2/HER2/neu)14. Initially investigated as a monotherapy and later in combination with chemotherapy,
trastuzumab significantly improved patient response rate, time
to progression, and overall survival compared to chemotherapy
alone14. However, its use is limited only to HER2-positive breast
cancers, the expression of which, as explained in the next section
of this review, may not be constant between primary tumors and
metastases, reducing the effectiveness of this strategy.
Based on their specific role in the metastatic cascade, potential
molecular targets for therapeutic intervention can be categorized
as involved in either metastasis initiation or progression15,16. Due
to the early dissemination of tumor cells, which is discussed in the
next section, molecules important in metastasis initiation, such as
regulation of cellular motility, angiogenesis, and invasion of local
extracellular matrix (ECM), may not be efficient targets for preventing metastatic disease since patients at risk already have disseminated cells by the time of primary tumor diagnosis. However, if
those molecules also play key roles in the later stages (progression)
of metastasis, such as continued trafficking after initial escape from
the primary tumor17, their targeting might be of clinical importance.
In particular, molecules that promote survival at the distant sites,
the dormancy-to-proliferation switch, and colonization of distant
organs are very attractive targets for drug development.
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The molecules identified and currently being investigated comprise
both the tumor cell autologous factors, such as those involved in
signal transduction, adhesion, motility, growth and survival, and
the microenvironmental factors, including resident stromal cells,
components of the immune system, chemokines, and promoters
of angiogenesis. A growing catalog of potential molecular targets
identified for inhibition of metastatic progression has been extensively reviewed7,18,19, including a recent overview of drug candidates
in current pharmaceutical pipelines that target the mechanisms of
tumor cell migration20. Effective anti-metastatic therapies need to
address metastasis-specific characteristics that allow for the active
targeting of metastatic cells. In the next section, we will discuss in
more detail the challenges facing the treatment of metastasis from
the perspective of drug development, specifically heterogeneity
within and between metastases, as well as between metastases and
primary tumors, constraints in detection and analysis, and the timing of intervention.

Challenges in the treatment of metastatic disease
Dissemination
The logical approach to preventing metastatic disease is to inhibit
the initial dissemination step. Dissemination used to be considered
a late-stage event in the linear model of malignant disease evolution,
due to the time necessary to accumulate essential somatic mutations
required by tumor cells for motility and survival beyond the primary site. However, evidence from mouse models of spontaneous
mammary tumorigenesis has shown that tumor cells are able to disseminate to the bone marrow as early as four weeks of age, when
mammary tissue only appears in atypical ductal hyperplasia (ADH)
or ductal carcinoma in situ (DCIS) stages21. Lung micrometastases
in the BALB-NeuT model were found at 20 weeks, a full 3 weeks
before tumors became visibly invasive. Additionally, early disseminated tumor cells (DTCs)—cells that left the primary tumor and
spread to another tissue via the circulation—could be released from
growth arrest and had the capability to develop into metastases. The
clinical relevance of these findings was confirmed using bone marrow samples from 607 breast cancer patients at various stages of
disease, concluding that small tumors produced similar numbers
of DTCs to late-stage tumors. Other evidence, including metastasis without invasive cancer such as DCIS22, cancers of unknown
primary origin23, and accidental transfer of cancer from clinically
disease-free organ donors24 all supported the authors’ observations
of early dissemination. These reports suggest that breast cancer
patients likely have DTCs even before their primary cancer is diagnosed, making the targeting of the origin of metastatic disease a less
promising therapy option.

Metastatic dormancy
One of the major challenges facing oncologists, particularly in the
case of breast cancer, concerns DTCs that remain in tissues after
adjuvant therapy in a sub-clinical, currently undetectable state,
known as dormancy. Upon dissemination, cancer cells can enter
dormancy either as individual non-proliferative, quiescent cells
or as undetectable micrometastases held in a reduced or balanced
proliferative/apoptotic state by lack of adequate resources (angiogenic dormancy) or an active immune system (immunogenic
dormancy)25,26. These cells or micrometastases can eventually
re-emerge and become proliferative years after a patient is thought

to be cancer-free. Since the mechanisms of action of many cytotoxic therapies disrupt aspects of the mitotic process, these agents
are most likely ineffective against the low or non-proliferative dormant cells27. There is also accumulating evidence from experimental
models that activated survival mechanisms may be playing a role
in protecting DTCs25. Regardless of the exact mechanism, DTCs
are resistant to the broad-spectrum therapeutic strategies currently
in use. Targeted therapy may provide additional benefit, but therapeutic regimens based on the primary tumor may not be effective
in DTCs.

Heterogeneity between primary tumor and metastases
Accumulating evidence indicates that metastases can be genetically and phenotypically different from the primary tumor28. This
phenomenon has been reported for overt metastases that exhibit
the opposite estrogen receptor, progesterone receptor, or HER-2
expression profile of the primary tumor. A meta-analysis examining estrogen receptor, progesterone receptor, and/or HER-2 expression in patients’ primary breast tumors and matched recurrent
metastases included 48 studies published between 1983 and 201129
showing 20%, 33%, and 8% discordance for estrogen receptor, progesterone receptor, and HER-2 status, respectively, with a higher
prevalence of positive to negative conversion. The authors suggest
that this observation may be the result of individual DTCs reflecting
heterogeneity of receptor expression within the primary tumor. Following endocrine therapy, the remaining resistant subpopulations of
primary tumor cells are selectively able to disseminate to and grow
at secondary sites, producing metastases with a different receptor
expression profile than the majority of the original primary tumor.
Since treatments are often determined based on the characteristics
of the primary tumor, discordance between the primary tumor and
metastatic phenotypes can render the treatment ineffective against
DTCs. Conversely, some patients with receptor-negative primary
tumors but positive metastases may benefit from available targeted
therapies but currently are unlikely to receive these therapeutic
options due to the clinical characteristics of the primary tumor.
Heterogeneity amongst metastases
In addition to differences between primary and metastatic tumors,
there is also heterogeneity among individual metastases. More than
one million cells per gram of tumor can be shed from the primary
mass every day30 and these cells can come from any of the diverse
subpopulations that compose the tumor at any point during tumor
evolution. Therefore, the DTCs are a genetically and phenotypically heterogeneous group. However, not all of these cells have the
ability to grow into clinically relevant distant lesions, otherwise
every patient would have a high metastatic burden. In reality, the
metastatic process is incredibly inefficient31,32, suggesting a great
deal of selective pressure is experienced by DTCs and only those
with the proper combination of characteristics are able to successfully colonize a secondary site. Though the successfully metastatic
cells probably share many characteristics, the genetic changes that
underlie those characteristics may not be identical, resulting in
heterogeneity between metastases in addition to differences from
the primary tumor33. Similar to the evaluation of HER-2 expression between primary tumor and metastases discussed earlier, an
investigation into HER-2 expression revealed that 18% of metastases within the same patient showed discordant expression34. In
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another examination of single primary and metastatic breast cancer
cells using immunofluorescence in situ hybridization (iFISH), cancer subtype markers, and statistical analysis, investigators measured
genetic and phenotypic heterogeneity between distant metastases35.
These results indicated significant diversity between distant metastases within the same patient. Furthermore, the authors observed
substantial differences between metastases in the proportions of
cells displaying subtype markers, indicating both genetic and phenotypic differences were prevalent between distant metastases from
the same patient.

Pharmacokinetics
An additional challenge to successful treatment of metastatic disease is the ability to deliver the therapy to the metastatic tumor
cells. Metastases are often present in multiple sites within a patient
and drug accessibility between tissues, for example bone versus
lung, may be significantly different. Certain tissues may act as
“pharmacological sanctuaries” that protect cancer cells from available therapies due to barriers that prevent access to those cells.
Evidence suggests that at least some brain metastases are shielded
from pharmacologic intervention by the blood-brain barrier36. To
cure patients of metastatic disease, effective therapies will have to
be deliverable to all of the potential metastatic sites within the body.
Since microenvironments differ in various secondary sites, combination anti-metastasis therapies may be necessary to deal with both
intra-tumoral genetic heterogeneity as well as microenvironmentallyinduced heterogeneity.
In summary, current adjuvant therapies are expected to control
metastasis by targeting residual disease remaining after surgery.
However, the use of adjuvant therapy is estimated to reduce the
relative risk of relapse by only 19–37% depending on the age of
the patient37. Thus, neither the current cytotoxic nor targeted adjuvant approaches appear to be as effective at preventing metastases
as they are at targeting the primary tumor. Finding new molecular
targets for preventing the growth of metastatic tumors should be
based on the realization of how different this process is from early
tumorigenesis.

Take-home lessons for optimal design of future antimetastatic therapies
Based on our current knowledge of metastasis biology, we envision
a three-pronged strategy for clinical intervention for progressive disease: prevention, stasis, and destruction. The prevention arm would
be primarily applied as a neo-adjuvant therapy intended to reduce
the potential metastatic capacity of tumor cells naturally shed from
the primary tumor between diagnosis and surgical removal. As discussed above, this might require combination therapy for maximal
efficiency since it has been demonstrated that tumor cells use multiple motility mechanisms (amoeboid, epithelial-to-mesenchymal
transition, collective migration38) to initiate dissemination. This arm
might also be used to help suppress potential metastatic cells displaced during surgical resection itself. Since breast cancers undergo
early dissemination, the prevention strategy would not necessarily
be effective against cells that disseminated to distant sites prior to
diagnosis. For these cells, cytostatic or cytotoxic therapies need to
be developed, specific to the biology of disseminated cells, to either
hold the disseminated cells in a sub-clinical state for the remaining

natural lifetime of the patient, or to eliminate the metastatic “seed”
before it can establish clinically relevant lesions. Finally, for those
patients unfortunate enough to develop metastases, therapeutics
specifically developed and targeted to metastatic biology need to be
developed to reduce morbidity and mortality associated with these
secondary tumors.
For these strategies to work, appropriate targets that drive the
establishment and maintenance of metastasis have to be identified.
Regrettably, despite significant advances in our understanding of the
cellular biology of metastatic disease, our knowledge of metastasis
“driver” genes remains limited. This is due partially to the difficulty
of studying the process, since much of the important biology occurs
in a small fraction of disseminated single cells or micrometastases.
At present, it is not possible to easily identify those cells that will
evolve into macroscopic lesions for in depth analysis, or exactly
when that critical event occurs. In addition, metastatic samples are
difficult to obtain from human patients since they are not usually
resected, but instead are subject to systemic therapy. Thus, although
the common mutations that drive primary breast cancer are now
known thanks to large sequencing projects, much less is known
about the mutational spectrum in metastatic disease. Finally, there
may be many genes that are associated with metastatic progression. Analysis of gene expression-based prognostic signatures suggests that there may be hundreds or even thousands of genes whose
expression is correlated with the disease outcome39. Many of these
genes are most likely expressed in the tumor microenvironment and
therefore investigations solely in tumor cells have the potential to
miss important molecules targetable for clinical intervention.
Continued investigations based on the biology of primary tumors
for the development of novel therapeutics are clearly important, and
undoubtedly will provide additional benefit to patients. However, this
strategy is potentially fraught with dangers, since therapies that can
shrink primary tumors have been shown to have little effect, or even
potentially adverse effects, on metastatic disease40,41. Furthermore,
work from many laboratories has identified metastasis-associated
genes that are not frequently mutated during cancer progression
but are epigenetically silenced or exert their metastatic influence
through alterations at the transcriptional level. Our own laboratory
uses a meiotic genetics approach to identify somatically inherited
polymorphisms that affect patients’ susceptibility to metastasis.
This approach has generated a growing list of metastasis susceptibility genes with tumor-autonomous or stromal effects, including some with the potential to be actionable clinical targets42–48. The
results of these studies suggest that a more comprehensive examination of metastasis biology, incorporating both genomic and transcriptional landscape mapping, may provide an entirely different
set of genes that might be more advantageously targeted to specifically reduce metastatic burden, without necessarily impacting the
primary tumor.
Now that The Cancer Genome Atlas (TCGA) and other genomics
projects have provided detailed information regarding the etiology
of primary tumors, it is time to initiate similar projects for metastatic disease. Since metastatic tumors represent highly selected
cells from a subset of the primary tumor localized in completely
different microenvironments, these lesions should be recognized as
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related (but distinct) tumors with different biology. Thus, treatment
strategies that are developed based on specific features of metastasis biology, used in parallel with those designed against the primary
tumor, will provide a more effective method for combatting the
final lethal stages of neoplastic disease than those strategies developed solely against the primary tumor. A Metastasis Genome Atlas
Project would, however, have additional challenges compared to
the TCGA. The major challenge would be access to the metastatic
tumor samples since surgical resection of metastases is usually not
performed due to increased risk without perceived patient benefit.
In addition, metastatic tissue collected postmortem may be compromised or selected by therapies that potentially induce genomic
changes, complicating analysis and interpretation of the results.

Furthermore, it will be important to screen multiple metastases from
different secondary sites within individual patients to help identify
tissue-specific differences that might expose therapeutic vulnerabilities or resistance. Regardless of the challenges facing the Metastasis
Genome Atlas Project concept, improved therapeutic strategies to
reduce breast cancer morbidity and mortality would significantly
benefit from a better understanding of the biology underlying the
primary cause of patient distress, disseminated metastatic disease.
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prevention of further spread, eradication of (or maintenance of dormancy in) disseminated cells and, most
important of all, destruction of established micrometastases.
The latter is certainly the main challenge: most primary breast cancers are successfully and completely
removed by surgery, it is the already-disseminated tumor cells (DTC) that are the potential seeds of
destruction of a human life. Much attention has been given to the early stages of metastasis: release of
cells, motility, invasion, adhesion to endothelia, extravasation – perhaps because these steps are the
easiest to manipulate experimentally. The onus is now on scientists to address whether any of these
processes and their molecular mediators are still required once DTC are established at secondary sites.
We need to know if they represent the ‘starter motor’ (essential initially but redundant once the process is
underway) or the ‘engine’ (powering the continued progress) of metastases. Even if we can prevent
further spread, it is important to define whether existing micrometastases (probably generated very early
in the course of the disease) would prove fatal before any later waves of circulating cells take hold –
possibly a case of shutting the stable door after the horse has bolted.
Metastases break one of the fundamental ‘taboos’ of multicellular organisms – that of cells being able to
survive and thrive in quite disparate, alien tissue environments – they no longer ‘know their place’. If we
could define how this is achieved we may discover some common denominator actionable molecular
targets for intervention that could be effective against widespread metastatic disease. Such studies, with
the precision tools of genetic manipulation could perhaps be achieved in lower organisms as a starting
point.
So, key additional questions raised by this interesting piece are: which if any of the molecular
mechanisms required to initiate and maintain primary tumors are also essential for establishing
metastases and for how long do any such dependencies persist? Or are the determinants of successful
secondary colonisation quite distinct? Do different organs have similar or unique requirements that enable
cancer cells to form overt metastases? The paper touches on these considerations, but much more
research is required in this challenging area. It is therefore essential, as Hunter rightly states, to facilitate
better access to clinical material, especially relapsed and drug resistant secondary disease (which may
only be practical at autopsy).
Dr Hunter’s paper will certainly recalibrate the way we think about translational research in metastasis. It
should inspire new generations of basic scientists and clinicians to work together to tackle more logically
and effectively this last hurdle in our efforts to improve cure rates in breast and other cancers.
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This is a thoughtful and well-written short review of a clinically very important topic. This review presents a
synthesis of approaches to deal clinically with metastatic breast cancer, and will stimulate thought in the
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